We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
-1.96%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$114M
AUM Growth
-$29.8M
Cap. Flow
-$27M
Cap. Flow %
-23.68%
Top 10 Hldgs %
42.25%
Holding
85
New
11
Increased
13
Reduced
16
Closed
19

Top Buys

Rank Stock Value
1
VIRX
Viracta Therapeutics, Inc. Common Stock
VIRX
+$4.51M
2
IBB icon
iShares Biotechnology ETF
IBB
+$2.38M
3
BPMC
Blueprint Medicines
BPMC
+$2.19M
4
CDTX
Cidara Therapeutics
CDTX
+$1.66M
5
ADXS
Advaxis Inc
ADXS
+$1.57M

Top Sells

Rank Stock Value
1
VTAE
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
+$15M
2
CYNA
CYNAPSUS THERAPEUTICS INC COM PAR NO PAR (CANADA)
CYNA
+$9.26M
3
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$2.15M
4
BSTC
BioSpecifics Technologies Corp.
BSTC
+$1.81M
5
TSRO
TESARO, Inc.
TSRO
+$1.77M

Sector Composition

Rank Sector Weight
1 Healthcare 93.3%
2 Miscellaneous 6.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ATRC icon
1
AtriCure
ATRC
$2.47B
$10.2M 8.92%
518,946
-10,000
-2% -$181K
NXTM
2
DELISTED
NxStage Medical Inc.
NXTM
$6.19M 5.44%
236,119
-2,390
-1% -$59.1K
ALDR
3
DELISTED
Alder Biopharmaceuticals
ALDR
$4.6M 4.04%
221,013
+55,700
+34% +$1.45M
LOXO
4
DELISTED
Loxo Oncology, Inc
LOXO
$4.49M 3.94%
139,722
+9,500
+7% +$244K
LKFT
5
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$4.24M 3.73%
66,068
– –
VIRX
6
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$4.1M 3.61%
+32,388
New +$4.51M
XENE icon
7
Xenon Pharmaceuticals
XENE
$5.81B
$3.96M 3.48%
514,091
– –
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$3.72M 3.27%
98,370
+6,501
+7% +$246K
ONC
9
BeOne Medicines Ltd
ONC
$41.5B
$3.64M 3.2%
119,841
+29,699
+33% +$933K
DERM
10
DELISTED
Dermira, Inc.
DERM
$3M 2.63%
98,800
– –
FOMX
11
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
$2.98M 2.61%
268,067
-10,000
-4% -$94.1K
PODD icon
12
Insulet
PODD
$10.1B
$2.77M 2.43%
73,484
– –
AGTC
13
DELISTED
Applied Genetic Technologies Corporation
AGTC
$2.68M 2.35%
286,298
+46,000
+19% +$414K
CYTK icon
14
Cytokinetics
CYTK
$10B
$2.56M 2.24%
210,306
+28,569
+16% +$303K
NBIX icon
15
Neurocrine Biosciences
NBIX
$15.7B
$2.56M 2.24%
66,008
+2,000
+3% +$90.5K
ARDX icon
16
Ardelyx
ARDX
$984M
$2.47M 2.17%
173,995
-45,100
-21% -$640K
IBB icon
17
iShares Biotechnology ETF
IBB
$10.5B
$2.31M 2.03%
+26,100
New +$2.38M
TSRO
18
DELISTED
TESARO, Inc.
TSRO
$2.08M 1.83%
15,500
-14,000
-47% -$1.77M
IMMU
19
DELISTED
Immunomedics Inc
IMMU
$2.05M 1.8%
559,674
-7,122
-1% -$21.1K
RDUS
20
DELISTED
Radius Health, Inc.
RDUS
$2.05M 1.8%
53,854
+17,000
+46% +$809K
BPMC
21
DELISTED
Blueprint Medicines
BPMC
$2.03M 1.79%
+72,500
New +$2.19M
TVRD
22
Tvardi Therapeutics
TVRD
$24.3M
$1.95M 1.71%
5,820
-1,598
-22% -$513K
DSCI
23
DELISTED
Derma Sciences, Inc. Common Stock (DE)
DSCI
$1.84M 1.62%
353,718
– –
MGNX icon
24
MacroGenics
MGNX
$263M
$1.82M 1.6%
89,200
+35,000
+65% +$881K
BEAT
25
DELISTED
BioTelemetry, Inc.
BEAT
$1.68M 1.47%
75,000
-5,000
-6% -$97.8K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2016 Portfolio in Review

As of Q4 2016, DAFNA Capital Management held 85 positions worth $114M, down 21% from $144M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

DAFNA Capital Management withdrew a net $27M in Q4 2016, closing 19 positions and reducing 16 holdings. Its most notable exit was VITAE PHARMACEUTICALS INC COMMON STOCK, an estimated $15M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 93% of assets, up from 79% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Viracta Therapeutics, Inc. Common Stock worth $4.1M.

  • DAFNA Capital Management's largest Q4 2016 buy was Viracta Therapeutics, Inc. Common Stock: 32,388 shares worth $4.1M.
  • DAFNA Capital Management added most to Alder Biopharmaceuticals in Q4 2016, an estimated $1.45M increase.
  • DAFNA Capital Management's biggest Q4 2016 reduction was TESARO, Inc., cutting an estimated $1.77M.
  • DAFNA Capital Management fully exited VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2016, selling an estimated $15M.
  • DAFNA Capital Management's ten largest holdings make up 42% of its $114M portfolio in Q4 2016.
  • DAFNA Capital Management opened 11 new positions and closed 19 in Q4 2016.
  • DAFNA Capital Management's portfolio value fell 21% quarter-over-quarter to $114M.

Based on DAFNA Capital Management's 13F filing for Q4 2016, filed 14 Feb 2017.